150 related articles for article (PubMed ID: 35259855)
1. Magnetic labeling of primary murine monocytes using very small superparamagnetic iron oxide nanoparticles.
Pohland M; Pohland C; Kiwit J; Glumm J
Neural Regen Res; 2022 Oct; 17(10):2311-2315. PubMed ID: 35259855
[TBL] [Abstract][Full Text] [Related]
2. Biocompatibility of very small superparamagnetic iron oxide nanoparticles in murine organotypic hippocampal slice cultures and the role of microglia.
Pohland M; Glumm R; Wiekhorst F; Kiwit J; Glumm J
Int J Nanomedicine; 2017; 12():1577-1591. PubMed ID: 28280327
[TBL] [Abstract][Full Text] [Related]
3. Rapid binding of electrostatically stabilized iron oxide nanoparticles to THP-1 monocytic cells via interaction with glycosaminoglycans.
Ludwig A; Poller WC; Westphal K; Minkwitz S; Lättig-Tünnemann G; Metzkow S; Stangl K; Baumann G; Taupitz M; Wagner S; Schnorr J; Stangl V
Basic Res Cardiol; 2013 Mar; 108(2):328. PubMed ID: 23314954
[TBL] [Abstract][Full Text] [Related]
4. Magnetic Particle Spectroscopy Reveals Dynamic Changes in the Magnetic Behavior of Very Small Superparamagnetic Iron Oxide Nanoparticles During Cellular Uptake and Enables Determination of Cell-Labeling Efficacy.
Poller WC; Löwa N; Wiekhorst F; Taupitz M; Wagner S; Möller K; Baumann G; Stangl V; Trahms L; Ludwig A
J Biomed Nanotechnol; 2016 Feb; 12(2):337-46. PubMed ID: 27305767
[TBL] [Abstract][Full Text] [Related]
5. Europium doping of superparamagnetic iron oxide nanoparticles enables their detection by fluorescence microscopy and for quantitative analytics.
Kobayashi Y; Hauptmann R; Kratz H; Ebert M; Wagner S; Taupitz M
Technol Health Care; 2017; 25(3):457-470. PubMed ID: 27935574
[TBL] [Abstract][Full Text] [Related]
6. Application of Europium-Doped Very Small Iron Oxide Nanoparticles to Visualize Neuroinflammation with MRI and Fluorescence Microscopy.
Millward JM; Ariza de Schellenberger A; Berndt D; Hanke-Vela L; Schellenberger E; Waiczies S; Taupitz M; Kobayashi Y; Wagner S; Infante-Duarte C
Neuroscience; 2019 Apr; 403():136-144. PubMed ID: 29273325
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance imaging of liver metastases: experimental comparison of anionic and conventional superparamagnetic iron oxide particles with a hepatobiliary contrast medium during dynamic and uptake phases.
Kaufels N; Korn R; Wagner S; Schink T; Hamm B; Taupitz M; Schnorr J
Invest Radiol; 2008 Jul; 43(7):496-503. PubMed ID: 18580332
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of acid-stabilized iron oxide nanoparticles and comparison for targeting atherosclerotic plaques: evaluation by MRI, quantitative MPS, and TEM alternative to ambiguous Prussian blue iron staining.
Scharlach C; Kratz H; Wiekhorst F; Warmuth C; Schnorr J; Genter G; Ebert M; Mueller S; Schellenberger E
Nanomedicine; 2015 Jul; 11(5):1085-95. PubMed ID: 25659644
[TBL] [Abstract][Full Text] [Related]
9. [Labeling of mesenchymal stem cells with different superparamagnetic particles of iron oxide and detectability with MRI at 3T].
Ittrich H; Lange C; Dahnke H; Zander AR; Adam G; Nolte-Ernsting C
Rofo; 2005 Aug; 177(8):1151-63. PubMed ID: 16021549
[TBL] [Abstract][Full Text] [Related]
10. New generation of monomer-stabilized very small superparamagnetic iron oxide particles (VSOP) as contrast medium for MR angiography: preclinical results in rats and rabbits.
Taupitz M; Schnorr J; Abramjuk C; Wagner S; Pilgrimm H; Hünigen H; Hamm B
J Magn Reson Imaging; 2000 Dec; 12(6):905-11. PubMed ID: 11105029
[TBL] [Abstract][Full Text] [Related]
11. Repeated Injection of Very Small Superparamagnetic Iron Oxide Particles (VSOPs) in Murine Atherosclerosis: A Safety Study.
Haase T; Ludwig A; Stach A; Mohtashamdolatshahi A; Hauptmann R; Mundhenk L; Kratz H; Metzkow S; Kader A; Freise C; Mueller S; Stolzenburg N; Radon P; Liebl M; Wiekhorst F; Hamm B; Taupitz M; Schnorr J
Nanomaterials (Basel); 2024 Apr; 14(9):. PubMed ID: 38727367
[TBL] [Abstract][Full Text] [Related]
12. Initial interaction of citrate-coated iron oxide nanoparticles with the glycocalyx of THP-1 monocytes assessed by real-time magnetic particle spectroscopy and electron microscopy.
Poller WC; Löwa N; Schleicher M; Münster-Wandowski A; Taupitz M; Stangl V; Ludwig A; Wiekhorst F
Sci Rep; 2020 Feb; 10(1):3591. PubMed ID: 32107402
[TBL] [Abstract][Full Text] [Related]
13. Very small superparamagnetic iron oxide nanoparticles: Long-term fate and metabolic processing in atherosclerotic mice.
Poller WC; Pieber M; Boehm-Sturm P; Ramberger E; Karampelas V; Möller K; Schleicher M; Wiekhorst F; Löwa N; Wagner S; Schnorr J; Taupitz M; Stangl K; Stangl V; Ludwig A
Nanomedicine; 2018 Nov; 14(8):2575-2586. PubMed ID: 30179669
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic effects of iron oxide nanoparticles and implications for safety in cell labelling.
Soenen SJ; Himmelreich U; Nuytten N; De Cuyper M
Biomaterials; 2011 Jan; 32(1):195-205. PubMed ID: 20863560
[TBL] [Abstract][Full Text] [Related]
15. Iron oxide magnetic nanoparticles highlight early involvement of the choroid plexus in central nervous system inflammation.
Millward JM; Schnorr J; Taupitz M; Wagner S; Wuerfel JT; Infante-Duarte C
ASN Neuro; 2013; 5(1):e00110. PubMed ID: 23452162
[TBL] [Abstract][Full Text] [Related]
16. Magnetic labeling of non-phagocytic adherent cells with iron oxide nanoparticles: a comprehensive study.
Boutry S; Brunin S; Mahieu I; Laurent S; Vander Elst L; Muller RN
Contrast Media Mol Imaging; 2008; 3(6):223-32. PubMed ID: 19072771
[TBL] [Abstract][Full Text] [Related]
17. Current status of superparamagnetic iron oxide contrast agents for liver magnetic resonance imaging.
Wang YX
World J Gastroenterol; 2015 Dec; 21(47):13400-2. PubMed ID: 26715826
[TBL] [Abstract][Full Text] [Related]
18. Contrast-enhanced MR imaging of atherosclerosis using citrate-coated superparamagnetic iron oxide nanoparticles: calcifying microvesicles as imaging target for plaque characterization.
Wagner S; Schnorr J; Ludwig A; Stangl V; Ebert M; Hamm B; Taupitz M
Int J Nanomedicine; 2013; 8():767-79. PubMed ID: 23450179
[TBL] [Abstract][Full Text] [Related]
19. Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro.
Metz S; Bonaterra G; Rudelius M; Settles M; Rummeny EJ; Daldrup-Link HE
Eur Radiol; 2004 Oct; 14(10):1851-8. PubMed ID: 15249981
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
